Dec 18 (Reuters) - Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. (Reporting by Mariam Sunny in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | 0.00% | -0.53% | -17.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.47% | 69.65M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- CKPT Stock
- News Checkpoint Therapeutics, Inc.
- US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy